December 6, 2019 / 10:14 PM / a month ago

Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial

(Reuters) - Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study.

The study evaluated the efficacy and safety of the therapy, Ide-cel, in patients who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, the companies said.

Reporting by Dania Nadeem in Bengaluru; Editing by Shailesh Kuber

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below